Analyst Price Targets — IMTX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 19, 2026 12:17 pm | Graig Suvannavejh | Mizuho Securities | $25.00 | $9.95 | TheFly | Immatics price target raised to $25 from $23 at Mizuho |
| December 4, 2025 12:20 pm | Jonathan Chang | Leerink Partners | $17.00 | $10.14 | StreetInsider | Immatics (IMTX) PT Raised to $17 at Leerink Partners |
| October 29, 2025 12:50 pm | Graig Suvannavejh | Mizuho Securities | $19.00 | $10.36 | TheFly | Immatics price target raised to $19 from $16 at Mizuho |
| September 17, 2025 8:21 pm | Paul Jeng | Guggenheim | $16.00 | $6.03 | TheFly | Immatics initiated with a Buy at Guggenheim |
| May 16, 2024 6:36 am | Graig Suvannavejh | Mizuho Securities | $16.00 | $11.08 | TheFly | Immatics price target raised to $16 from $14 at Mizuho |
| August 9, 2022 6:31 pm | Geulah Livshits | Chardan Capital | $28.00 | $12.43 | TheFly | Immatics price target lowered to $28 from $30 at Chardan |
Latest News for IMTX
Houston, Texas and Tuebingen, Germany, July 17, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, today announced three presentations at the European Society for Medical Oncology (ESMO) Congress 2026, to be held from October 23-27, 2026, in Madrid, Spain.
Houston, Texas and Tuebingen, Germany, July 17, 2026 - Immatics N. V. (NASDAQ: IMTX, "Immatics" or the "Company"), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, today announced three presentations at the European Society for Medical Oncology (ESMO) Congress 2026, to be held from October 23-27, 2026, in Madrid, Spain.
Immatics is evolving into a PRAME-focused oncology platform with three monetization paths, not just a single-asset cell therapy play. IMTX's lead asset, anzu-cel, is in Phase 3 for advanced melanoma, but broader value lies in its layered PRAME franchise and pipeline expansion. IMTX maintains a strong cash runway into 2028, enabling critical clinical milestones without distressed financing or near-term capital risk.
Houston, Texas and Tuebingen, Germany , June 1, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, today announced extended data from the ongoing Phase 1b clinical trial evaluating anzu-cel (anzutresgene autoleucel, IMA203) PRAME TCR T-cell therapy in heavily pretreated…
One-time infusion of anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy induced rapid, deep and durable systemic anti-tumor activity in metastatic PD-1 relapsed cutaneous melanoma and metastatic uveal melanomaAnzu-cel showed a 56% confirmed ORR, 14. 6 months mDOR, 6. 1 months mPFS and 16. 2 months mOS at longer follow-up alongside a predictable and manageable tolerability profile in metastatic melanoma…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for IMTX.
U.S. House Trading
No House trades found for IMTX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.